ライフサイエンスコーパス: anticardiolipin

1 including lupus anticoagulants (LAC) and/or anticardiolipin Ab (aCL), and thrombosis is recognized a

2 smatch (P = .003), positive test results for anticardiolipin (ACA) IgG (P = .03) or antiparietal anti

3 Immunoglobulin G (IgG) anticardiolipin (aCL) antibodies are associated with val

4 The association of anticardiolipin (aCL) antibodies with coronary artery di

5 Anticardiolipin (aCL) autoantibodies are associated with

6 The dependence of anticardiolipin (aCL) binding on the presence of beta 2-

7 s were screened for IgG and IgM aPL using an anticardiolipin (aCL) enzyme-linked immunosorbent assay.

8 The anticardiolipin (aCL) test has been widely used by physi

9 alpha-PC) and beta2-glycoprotein-1-dependent anticardiolipin (alpha-CL), and these antibodies may lin

10 Sera were tested for anticardiolipin and anti-Sm/RNP antibodies.

11 tes developed antinuclear autoantibodies and anticardiolipin and anti-ssDNA antibodies.

12 smic, antiendothelial cell, antiphospholipid/anticardiolipin and antithyroid antibodies) are used whe

13 had positive results of lupus anticoagulant, anticardiolipin, and anti-beta(2)-glycoprotein I antibod

14 i-double-stranded DNA (anti-dsDNA), anti-Sm, anticardiolipin, and anti-ribosomal P autoantibodies and

15 Anticardiolipin (anti-CL) antibodies, diagnostic for ant

16 Recently, anticardiolipin antibodies (ACA) have been linked with c

17 e (APAS) is characterized by the presence of anticardiolipin antibodies (ACA) in association with thr

18 Antiphospholipid antibodies, including anticardiolipin antibodies (ACA), are strongly associate

19 trongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to prot

20 lls treated with a range of human monoclonal anticardiolipin antibodies (aCL) (as anti-beta2-glycopro

21 Yet, standard anticardiolipin antibodies (aCL) immunoassays routinely

22 anti-beta2-glycoprotein I (anti-beta2GPI) or anticardiolipin antibodies (aCL) may be implicated in th

23 Mice infused with IgG containing human anticardiolipin antibodies (aCL) were treated with IVIG

24 Anti-MDA-LDL, anticardiolipin antibodies (aCL), and anti-beta2-glycopr

25 A, C, B/B', and D, for anti-U1 RNA, and for anticardiolipin antibodies (aCL).

26 had lupus anticoagulant and/or high titer of anticardiolipin antibodies (aCL).

27 d lupus anticoagulant (LA) or high titers of anticardiolipin antibodies (ACLAs), either immunoglobuli

28 Anticardiolipin antibodies (antiCl), present in some pat

29 nt with acute Q fever and high levels of IgG anticardiolipin antibodies (IgG aCL).

30 Anticardiolipin antibodies and anti-beta2GPI were presen

31 otein(a), homocysteine, lupus anticoagulant, anticardiolipin antibodies and genotyping of factor V Le

32 f CL is needed to generate epitopes for many anticardiolipin antibodies and that some of these epitop

33 Anticardiolipin antibodies appeared from 7.6 years prior

34 Our findings indicate that anticardiolipin antibodies are frequently elevated in pa

35 We recently suggested that many anticardiolipin antibodies bind only to oxidized cardiol

36 relationship between dyslipoproteinemia and anticardiolipin antibodies has been demonstrated.

37 and technical complications, but the role of anticardiolipin antibodies has not been evaluated.

38 Lupus anticoagulants and anticardiolipin antibodies have been strongly associated

39 strated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties

40 ted the possible association between HAT and anticardiolipin antibodies in adult patients who underwe

41 Other potential consequences of anticardiolipin antibodies in end-stage liver disease re

42 Anticardiolipin antibodies in SLE patients tend to prece

43 ity for lupus anticoagulant (P < 0.0001) and anticardiolipin antibodies of the IgG (P = 0.035) or the

44 Determination of IgM and IgG anticardiolipin antibodies was performed by enzyme-linke

45 iciency, activated protein C resistance, and anticardiolipin antibodies) at predictably greater risk

46 atients with stroke associated with elevated anticardiolipin antibodies, and we discuss their managem

47 Ls were measured longitudinally: 3 in serum (anticardiolipin antibodies, beta2-glycoprotein I, and an

48 nd 1 patient each with protein C deficiency, anticardiolipin antibodies, factor VII mutation, factor

49 luded if they had moderate or high levels of anticardiolipin antibodies, lupus anticoagulant, or a hi

50 of Raynaud's phenomenon, as well as elevated anticardiolipin antibodies, lupus anticoagulant, or a hi

51 e not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or prev

52 Antiphospholipid antibodies including anticardiolipin antibodies, lupus anticoagulants, and an

53 and the presence of the lupus anticoagulant, anticardiolipin antibodies, or anti-beta(2)-glycoprotein

54 coagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuati

55 ding; and those who had detectable levels of anticardiolipin antibodies.

56 , thrombin, APC, and plasmin, as well as for anticardiolipin antibody (aCL) activity.

57 rotein AI to OxCL-coated wells increased the anticardiolipin antibody (aCL) binding from APS sera tha

58 uble-stranded DNA (anti-dsDNA) antibody, and anticardiolipin antibody (aCL), as well as proteinuria a

59 La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody [aCL]) were selected for cluste

60 of 35 (63%) liver recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >

61 either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separat

62 ng anticoagulant therapy in patients with an anticardiolipin antibody was 1.53 (95% CI, 0.76-3.11), a

63 ter IgG or IgM anticardiolipin antibody, IgA anticardiolipin antibody, and anti-beta2-glycoprotein I

64 aris, thrombocytopenia, low-titer IgG or IgM anticardiolipin antibody, IgA anticardiolipin antibody,

65 in lymphocyte count or serum immunoglobulin, anticardiolipin antibody, or rubella IgG antibody concen

66 Reactive antibodies to lupus anticoagulant, anticardiolipin, antithrombin III, and the translational

67 IgG and IgM aCL were measured using an anticardiolipin assay.

68 beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin autoantibodies (aCl) are associated with

69 protective effect against the production of anticardiolipin autoantibodies (Ptrend=1.6x10(-4), ORhig

70 pholipid antibodies (aPL) were identified by anticardiolipin enzyme-linked immunosorbent assay (ELISA

71 ntibodies were present(defined as IgG or IgM anticardiolipin > or =40 IU/ml or the presence of lupus

72 Being positive for anticardiolipin immunoglobulin M antibodies was a risk f

73 antigens, such as cathepsin G, elastase, and anticardiolipin, may also be detected in some patients.

74 holipid antibodies and persistently positive anticardiolipin or lupus anticoagulant positive tests.

75 ant treatment at baseline, or positivity for anticardiolipin- or anti-beta2-glycoprotein I antibodies

76 s with HAT also tended to have a higher mean anticardiolipin titer of IgG and IgM and a lower pretran